BACKGROUND AND PURPOSE: Humanized mice for the nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ), termed PPARδ knock-in (PPARδ KI) mice, were generated for the investigation of functional differences between mouse and human PPARδ and as tools for early drug efficacy assessment. EXPERIMENTAL APPROACH: Human PPARδ function in lipid metabolism was assessed at baseline, after fasting or when challenged with the GW0742 compound in mice fed a chow diet or high-fat diet (HFD). KEY RESULTS: Analysis of PPARδ mRNA levels revealed a hypomorph expression of human PPARδ in liver, macrophages, small intestine and heart, but not in soleus and quadriceps muscles, white adipose tissue and skin. PPARδ KI mice displayed a small decrease of high-density lipoprotein-cholesterol whereas other lipid parameters were unaltered. Plasma metabolic parameters were similar in wild-type and PPARδ KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARδ. Gene expression profiling in liver, soleus muscle and macrophages showed similar gene patterns regulated by mouse and human PPARδ. The anti-inflammatory potential of human PPARδ was also similar to mouse PPARδ in liver and isolated macrophages. CONCLUSIONS AND IMPLICATIONS: These data indicate that human PPARδ can compensate for mouse PPARδ in the regulation of lipid metabolism and inflammation. Overall, this novel PPARδ KI mouse model shows full responsiveness to pharmacological challenge and represents a useful tool for the preclinical assessment of PPARδ activators with species-specific activity.
BACKGROUND AND PURPOSE: Humanized mice for the nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ), termed PPARδ knock-in (PPARδ KI) mice, were generated for the investigation of functional differences between mouse and human PPARδ and as tools for early drug efficacy assessment. EXPERIMENTAL APPROACH: Human PPARδ function in lipid metabolism was assessed at baseline, after fasting or when challenged with the GW0742 compound in mice fed a chow diet or high-fat diet (HFD). KEY RESULTS: Analysis of PPARδ mRNA levels revealed a hypomorph expression of human PPARδ in liver, macrophages, small intestine and heart, but not in soleus and quadriceps muscles, white adipose tissue and skin. PPARδ KI mice displayed a small decrease of high-density lipoprotein-cholesterol whereas other lipid parameters were unaltered. Plasma metabolic parameters were similar in wild-type and PPARδ KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARδ. Gene expression profiling in liver, soleus muscle and macrophages showed similar gene patterns regulated by mouse and human PPARδ. The anti-inflammatory potential of human PPARδ was also similar to mouse PPARδ in liver and isolated macrophages. CONCLUSIONS AND IMPLICATIONS: These data indicate that human PPARδ can compensate for mouse PPARδ in the regulation of lipid metabolism and inflammation. Overall, this novel PPARδ KI mouse model shows full responsiveness to pharmacological challenge and represents a useful tool for the preclinical assessment of PPARδ activators with species-specific activity.
Authors: W Xie; J L Barwick; M Downes; B Blumberg; C M Simon; M C Nelson; B A Neuschwander-Tetri; E M Brunt; P S Guzelian; R M Evans Journal: Nature Date: 2000-07-27 Impact factor: 49.962
Authors: Dennis L Sprecher; Christine Massien; Greg Pearce; Andrew N Billin; Itay Perlstein; Timothy M Willson; David G Hassall; Nicolas Ancellin; Scott D Patterson; David C Lobe; Tony G Johnson Journal: Arterioscler Thromb Vasc Biol Date: 2006-11-16 Impact factor: 8.311
Authors: W R Oliver; J L Shenk; M R Snaith; C S Russell; K D Plunket; N L Bodkin; M C Lewis; D A Winegar; M L Sznaidman; M H Lambert; H E Xu; D D Sternbach; S A Kliewer; B C Hansen; T M Willson Journal: Proc Natl Acad Sci U S A Date: 2001-04-17 Impact factor: 11.205
Authors: Ulf Risérus; Dennis Sprecher; Tony Johnson; Eric Olson; Sandra Hirschberg; Aixue Liu; Zeke Fang; Priti Hegde; Duncan Richards; Leli Sarov-Blat; Jay C Strum; Samar Basu; Jane Cheeseman; Barbara A Fielding; Sandy M Humphreys; Theodore Danoff; Niall R Moore; Peter Murgatroyd; Stephen O'Rahilly; Pauline Sutton; Tim Willson; David Hassall; Keith N Frayn; Fredrik Karpe Journal: Diabetes Date: 2007-11-16 Impact factor: 9.461
Authors: John S Welch; Mercedes Ricote; Taro E Akiyama; Frank J Gonzalez; Christopher K Glass Journal: Proc Natl Acad Sci U S A Date: 2003-05-09 Impact factor: 11.205
Authors: Linda M Sanderson; Tatjana Degenhardt; Arjen Koppen; Eric Kalkhoven; Beatrice Desvergne; Michael Müller; Sander Kersten Journal: Mol Cell Biol Date: 2009-10-05 Impact factor: 4.272
Authors: François Briand; Snehal U Naik; Ilia Fuki; John S Millar; Colin Macphee; Max Walker; Jeffrey Billheimer; George Rothblat; Daniel J Rader Journal: Clin Transl Sci Date: 2009-04 Impact factor: 4.438
Authors: Anny Devoy; Rosie K A Bunton-Stasyshyn; Victor L J Tybulewicz; Andrew J H Smith; Elizabeth M C Fisher Journal: Nat Rev Genet Date: 2011-12-16 Impact factor: 53.242
Authors: Larry G Higgins; Wojciech G Garbacz; Mattias C U Gustafsson; Sitheswaran Nainamalai; Peter R Ashby; C Roland Wolf; Colin N A Palmer Journal: PPAR Res Date: 2012-03-21 Impact factor: 4.964